secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2023-04-14T23:59:59+00:00
Accession:  0001193125-23-102213
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma implements 1-for-20 reverse stock split to meet Nasdaq bid price rule
--------------------------------------------------------------------------------

- Board set ratio at 1-for-20; filed Certificate of Amendment with Delaware on April 14, 2023.
- Outstanding shares reduced from ~133.3M to ~6.7M; no fractional shares issued, cash in lieu.
- Stockholders approved reverse split on Jan 5, 2023; trading starts post-split April 17 under MEIP.
- New CUSIP 55279B301; exercise prices of options/warrants proportionally adjusted.
- Computershare acting as transfer agent; book-entry holders need no action.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523102213/0001193125-23-102213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523102213/d483010d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-102213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer